



6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sciforum.net/conference/ECMC2020

sponsored by



pharmaceuticals

Novel bridged heteronuclear Pt(II)-L-Zn(II) complexes with promising antitumor activity

**Tanja Soldatović^{1,*}, Enisa Selimović¹, Nevena Milivojević^{2,3}, Milena Jovanović³,
Biljana Šmit², and Katarina Virijević²**

¹ Department of Chemical-Technological Science, State University of Novi Pazar, Vuka Karadžića bb, 36300 Novi Pazar, Serbia;


² Institute for Information Technologies, Department of Science, University of Kragujevac, Jovana Cvijića bb, 34000 Kragujevac, Serbia;

³ Faculty of Science, Department for Biology and Ecology, University of Kragujevac, Radoja Domanovića 12, 34000 Kragujevac, Serbia.

* Corresponding author: tsoldatovic@np.ac.rs



Novel bridged heteronuclear Pt(II)-L-Zn(II) complexes with promising antitumor activity



6th International Electronic Conference on
Medicinal Chemistry

1-30 November 2020

sponsored:



pharmaceuticals

Abstract: Design of novel heteronuclear platinum(II)-zinc(II) complexes as potential DNA and protein targeting metal-based anticancer agents could be beneficial. The compounds of these two metal ions have different coordination geometry, kinetics properties, affinity, and reactivity towards biologically relevant nucleophiles. According to hard-soft acid base principle, different reactivities of metal centers will result in different coordination modes of biomolecules and in increment of cytotoxicity.

The novel heteronuclear complexes [*cis*-PtCl(NH₃)(μ-pyrazine)ZnCl(terpy)](ClO₄)₂ (**Pt-L1-Zn**) and [*cis*-PtCl(NH₃)(μ-4,4'-bipyridyl)ZnCl(terpy)](ClO₄)₂ (**Pt-L2-Zn**) (where terpy = 2,2':6',2''-terpyridine, L1 = pyrazine, L2 = 4,4'-bipyridyl) were synthesized and characterized. The cytotoxic activity of heteronuclear **Pt-L1-Zn** and **Pt-L2-Zn** complexes was determined on human colorectal cancer cell line (HCT-116) and human breast cancer cell line (MDA-MB-231). Both complexes significantly reduced cell viability on tested cell lines and exerted significant cytotoxic effects, with better effect on HCT-116 cells than cisplatin, especially after 72 h (IC₅₀ < 0.52 mM). The Pt-L2-Zn complex showed higher activity against human breast cancer cells (MDA-MB-231) than cisplatin after 72 h. The higher reactivity toward DNA constituent and significant cytotoxic activity may be attributed to the different geometries, Lewis acidity of different metal centers, as well as choice of bridging ligands.

Keywords: cytotoxic activity; heteronuclear complexes; platinum(II); structure-reactivity correlation; zinc(II)






Introduction

Design of novel heteronuclear platinum(II)-zinc(II) complexes as potential DNA and protein targeting metal-based anticancer agents could be beneficial. The compounds of these two metal ions have different coordination geometry, kinetics properties, affinity and reactivity towards biologically relevant nucleophiles. According to hard-soft acid base principle, dissimilar reactivity of metal centers will result in different coordination modes of biomolecules and in increment of cytotoxicity.^[1]

^[1] T.V. Soldatović, *Application of the principle of hard and soft acids and bases to mechanisms of bioinorganic reaction*, Livre de Lyon Publisher, Lyon, France, 2019



Results and discussion



Synthesis and characterisation of the heteronuclear complexes with general formula Pt(II)-L-Zn(II) starting from square-planar Pt(II) and square-pyramidal Zn(II) complexes using various types of bridging ligands

Investigation of interactions with biologically relevant molecules such as guanosine-5'-monophosphate (5'-GMP), inosine-5'-monophosphate (5'-IMP) and glutathione (GSH)

Evaluation of the cytotoxic effect of heteronuclear **Pt-L-Zn** complexes on human colorectal cancer cell line (HCT-116) and human breast cancer cell line (MDA-MB-231)

Soldatović, T., et al. *Appl. Organomet. Chem.* **2020**, DOI: 10.1002/aoc.5864



6th International Electronic Conference on
Medicinal Chemistry


1-30 November 2020

sponsored:



pharmaceuticals

Results and discussion



Soldatović, T., et al. *Appl. Organomet. Chem.* **2020**, DOI: 10.1002/aoc.5864




6th International Electronic Conference on
Medicinal Chemistry

1-30 November 2020



sponsored:



pharmaceuticals



Nu = 5'-GMP, 5'-IMP, GSH
 L = pyrazine, 4, 4'-bipyridyl



Pseudo-first-order rate constants plotted as a function of nucleophile concentration for the first (a) and second (b) substitution reactions of Pt-L1-Zn complex with 5'-GMP, 5'-IMP and GSH mixing at pH 7.4 (0.010 mol L⁻¹ Tris-HCl buffer) in addition of 0.005 mol L⁻¹ NaCl at 25 °C

Proposed pathways for the reaction of the heteronuclear Pt-L-Zn complexes with biologically relevant nucleophiles

Soldatović, T., et al. *Appl. Organomet. Chem.* **2020**, DOI: 10.1002/aoc.5864




6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sponsored:



pharmaceuticals



^1H NMR spectra of the reaction between **Pt-L2-Zn** complex with GSH in molar ratio 1:2 in D_2O

^1H NMR data of reaction between **Pt-L2-Zn** complexes and GSH exhibited upfield shifts of all signals corresponding to the complex. At initial stage coordination of GSH to the zinc(II) metal center was observed, and was confirmed by the shift of signal originated from $-\text{CH}_2(\text{COO}^-)$ protons in glycine side chain. The signal of $-\text{CH}_2(\text{COO}^-)$ protons in free GSH was at 4.58 ppm while coordinated (*via* oxygen) at 4.30 ppm. After several minutes doublet of doublet at 3.11 ppm of $-\text{CH}_2(\text{S})$ protons of the second coordinated GSH appeared and was shifted relative to free GSH (2.97 ppm), which confirmed coordination *via* sulfur to the platinum(II) center. The results are significant, as it is known that glutathione deactivates platinum drugs.

Soldatović, T., et al. *Appl. Organomet. Chem.* **2020**, DOI: 10.1002/aoc.5864




**6th International Electronic Conference on
Medicinal Chemistry**

1-30 November 2020

sponsored:



pharmaceuticals



The effect of **Pt-L1-Zn (a)** and **Pt-L2-Zn (b)** complex on the HCT-116 and MDA-MB-231 cell viability. All values are mean, n=6; percentages of viable cells

Soldatović, T., et al. *Appl. Organomet. Chem.* **2020**, DOI: 10.1002/aoc.5864



6th International Electronic Conference on Medicinal Chemistry

1-30 November 2020

sponsored:



pharmaceuticals

Conclusions

- Two new heteronuclear complexes [*cis*-PtCl(NH₃)(μ-pyrazine)ZnCl(terpy)](ClO₄)₂ (**Pt-L1-Zn**) and [*cis*-PtCl(NH₃)(μ-4,4'-bipyridyl)ZnCl(terpy)](ClO₄)₂ (**Pt-L2-Zn**) were synthesized and characterized.
- The kinetics of substitution reactions of the complexes with 5'-GMP, 5'-IMP and GSH were studied. The order of reactivity for the first substitution processes of both complexes is 5'-GMP > 5'-IMP > GSH, while for the second is 5'-IMP > GSH.
- The short distance between the two metal centers involves electrostatic interaction between the metals that increased the electrophilicity of both Zn(II) and Pt(II) centers. The first reaction step is accounted to reactivity of Zn(II) center, while the second to Pt(II). The increasing in electrophilicity of centers leads to lower p*K*_a values in the case of the diaqua **Pt-L1-Zn** complex (p*K*_{a1} = 3.47; p*K*_{a2} = 5.19) and also in increasing in reactivity.
- Two different metal centers, different in Lewis acidity and geometry in heteronuclear complexes, have great influence on the order of the reactivity and different coordination modes of biomolecules. The results gained a biological impact especially on the reactivity of 5'-GMP which is around 2-5.5 times higher than glutathione depending of the complex.
- The heteronuclear **Pt-L1-Zn** and **Pt-L2-Zn** complexes reduced HCT-116 and MDA-MB-231 cell viabilities. Significant cytotoxic effects were noticed, with better activity exerted on HCT-116 cells than cisplatin especially after 72 h (IC₅₀ < 0.52 mM). Also, the **Pt-L2-Zn** complex has shown better cytotoxic effect against MDA-MB-231 cells after 72 h cisplatin.
- Overall, we may conclude that heteronuclear complexes containing metals centers with different Lewis acidity, geometry and kinetic characteristics, connected with π-acceptor bridging ligands, could give promising antitumor activity.



Acknowledgments

The authors are grateful for the support to the Ministry of Education, Science and Technological Development of the Republic of Serbia. T. Soldatović and E. Selimović gratefully acknowledge financial support from State University of Novi Pazar, Novi Pazar, Republic of Serbia.



MINISTRY OF EDUCATION,
SCIENCE AND TECHNOLOGICAL DEVELOPMENT



SUNP



**6th International Electronic Conference on
Medicinal Chemistry**

1-30 November 2020

sponsored:



pharmaceuticals